Trials / Unknown
UnknownNCT01279967
A Clinical Trial of ADI-PEG 20TM in Patients With Malignant Pleural Mesothelioma
A Randomized Stratified Multicentre Phase II Clinical Trial of Single Agent ADI-PEG 20TM (Pegylated Arginine Deiminase) in Patients With Malignant Pleural Mesothelioma
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 70 (actual)
- Sponsor
- Barts & The London NHS Trust · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To examine whether the arginine depleting drug, ADI-PEG 20, might be effective as a targeted therapy in patients with ASS-negative malignant pleural mesothelioma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ADI-PEG 20 | 36.8mg/m2 based on BSA, weekly treatment for 6 months |
Timeline
- Start date
- 2011-01-01
- Primary completion
- 2015-01-01
- Completion
- 2015-03-01
- First posted
- 2011-01-20
- Last updated
- 2014-11-20
Locations
7 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT01279967. Inclusion in this directory is not an endorsement.